153 related articles for article (PubMed ID: 31488237)
1. Power Analysis and Sample Size Determination for Crossover Trials with Application to Bioequivalence Assessment of Topical Ophthalmic Drugs Using Serial Sampling Pharmacokinetic Data.
Yu YP; Yan XY; Yao C; Xia JL
Biomed Environ Sci; 2019 Aug; 32(8):614-623. PubMed ID: 31488237
[TBL] [Abstract][Full Text] [Related]
2. Estimation in AB/BA crossover trials with application to bioequivalence studies with incomplete and complete data designs.
Jaki T; Pallmann P; Wolfsegger MJ
Stat Med; 2013 Dec; 32(30):5469-83. PubMed ID: 23801551
[TBL] [Abstract][Full Text] [Related]
3. An approach for sample size determination of average bioequivalence based on interval estimation.
Chiang C; Hsiao CF
Stat Med; 2017 Mar; 36(7):1068-1082. PubMed ID: 28070984
[TBL] [Abstract][Full Text] [Related]
4. Equivalence assessment for interchangeability based on two-sided tests.
Dong X; Tsong Y
J Biopharm Stat; 2014; 24(6):1312-31. PubMed ID: 25032976
[TBL] [Abstract][Full Text] [Related]
5. On sample size calculation in bioequivalence trials.
Chow SC; Wang H
J Pharmacokinet Pharmacodyn; 2001 Apr; 28(2):155-69. PubMed ID: 11381568
[TBL] [Abstract][Full Text] [Related]
6. Sample size determination in bioequivalence studies using statistical assurance.
Ring A; Lang B; Kazaroho C; Labes D; Schall R; Schütz H
Br J Clin Pharmacol; 2019 Oct; 85(10):2369-2377. PubMed ID: 31276603
[TBL] [Abstract][Full Text] [Related]
7. Sample size determination for equivalence assessment with multiple endpoints.
Sun A; Dong X; Tsong Y
J Biopharm Stat; 2014; 24(6):1203-14. PubMed ID: 25032845
[TBL] [Abstract][Full Text] [Related]
8. Blinded sample size re-estimation in crossover bioequivalence trials.
Golkowski D; Friede T; Kieser M
Pharm Stat; 2014; 13(3):157-62. PubMed ID: 24715672
[TBL] [Abstract][Full Text] [Related]
9. Design and inference for 3-stage bioequivalence testing with serial sampling data.
Yan F; Zhu H; Liu J; Jiang L; Huang X
Pharm Stat; 2018 Sep; 17(5):458-476. PubMed ID: 29726096
[TBL] [Abstract][Full Text] [Related]
10. A note on sample size determination for bioequivalence studies with high-order crossover designs.
Chen KW; Chow SC; Li G
J Pharmacokinet Biopharm; 1997 Dec; 25(6):753-65. PubMed ID: 9697082
[TBL] [Abstract][Full Text] [Related]
11. A modified large sample approach in the assessment of population bioequivalence.
Quiroz J; Ting N; Wei GC; Burdick RK
J Biopharm Stat; 2000 Nov; 10(4):527-44. PubMed ID: 11104391
[TBL] [Abstract][Full Text] [Related]
12. Two-stage designs versus European scaled average designs in bioequivalence studies for highly variable drugs: Which to choose?
Molins E; Cobo E; Ocaña J
Stat Med; 2017 Dec; 36(30):4777-4788. PubMed ID: 28853164
[TBL] [Abstract][Full Text] [Related]
13. Sample Size Determination and Study Design Impact on Dose-Scale Pharmacodynamic Bioequivalence: a Case Study Using Orlistat.
Xu L; Li S; Wu W; Cheng Z; Xie F
AAPS J; 2024 Jul; 26(4):77. PubMed ID: 38960976
[TBL] [Abstract][Full Text] [Related]
14. A comparison of group sequential and fixed sample size designs for bioequivalence trials with highly variable drugs.
Knahl SIE; Lang B; Fleischer F; Kieser M
Eur J Clin Pharmacol; 2018 May; 74(5):549-559. PubMed ID: 29362819
[TBL] [Abstract][Full Text] [Related]
15. Sample size calculation for the Power Model for dose proportionality studies.
Sethuraman VS; Leonov S; Squassante L; Mitchell TR; Hale MD
Pharm Stat; 2007; 6(1):35-41. PubMed ID: 17323313
[TBL] [Abstract][Full Text] [Related]
16. On statistical power for average bioequivalence testing under replicated crossover designs.
Wan H; Chow SC
J Biopharm Stat; 2002 Aug; 12(3):295-309. PubMed ID: 12448572
[TBL] [Abstract][Full Text] [Related]
17. Alternative confidence intervals for the assessment of bioequivalence in four-period cross-over designs.
Quiroz J; Ting N; Wei GC; Burdick RK
Stat Med; 2002 Jul; 21(13):1825-47. PubMed ID: 12111892
[TBL] [Abstract][Full Text] [Related]
18. Bioequivalence studies: biometrical concepts of alternative designs and pooled analysis.
Zintzaras E; Bouka P
Eur J Drug Metab Pharmacokinet; 1999; 24(3):225-32. PubMed ID: 10716060
[TBL] [Abstract][Full Text] [Related]
19. Minimum sample size and sampling time requirements for assessment of rifampicin bioequivalence from FDC formulations.
Agrawal S; Kaur KJ; Singh I; Bhade S; Kaul CL; Panchagnula R
Int J Tuberc Lung Dis; 2005 Nov; 9(11):1273-80. PubMed ID: 16333937
[TBL] [Abstract][Full Text] [Related]
20. Exact calculation of power and sample size in bioequivalence studies using two one-sided tests.
Shen M; Russek-Cohen E; Slud EV
Pharm Stat; 2015; 14(2):95-101. PubMed ID: 25477145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
